■输液率是所有静脉注射顺序中应包括的基本要素之一。患者可能经历与不适当输注相关的不利后果或风险。同时,化疗部门迅速提供治疗的压力越来越大,高效,而且安全,因此,改善化疗流程和为癌症患者服务是非常必要的。临床医生应考虑如何进一步规范输液治疗,创新新的输液策略以提高疗效,减少毒性,提高患者满意度,节约卫生资源成本。零星研究评估了抗癌剂输注速率对临床结果的影响,经济效益,和行政效率。然而,更新审查尚未可用。
■相关文献是通过搜索PubMed确定的,直到2023年9月。
■输注率可能会对抗癌剂的功效产生重大影响(例如,甲氨蝶呤,氟尿嘧啶,和三氧化二砷)。缓慢输注铂化合物更安全,多柔比星和卡莫司汀,而快速输注比缓慢输注吉西他滨更安全。紫杉醇和氟尿嘧啶的最佳流速基于多种毒性风险之间的平衡。最佳输注速率可带来经济效益。如果疗效和安全性没有受到影响,缩短输液可能会导致更高的患者满意度,提高机构效率和更多可用于其他活动的护理时间(例如,生物类似产品,endostar)。其他有关输注速率的担忧包括临床适应症(例如,紫杉醇和利妥昔单抗,甲氨蝶呤),过敏反应的严重程度和类型(例如,铂化合物),配方特征(例如,紫杉醇,阿霉素),和遗传多态性(例如,吉西他滨,甲氨蝶呤)。
■有关输注速度的最新知识将提高静脉给药的适当性和准确性。跨学科团队应协作并实施相关的风险管理和医疗政策。值得进行不同输注速度的静脉治疗的比较研究。
UNASSIGNED: Infusion rate is one of the essential elements that should be included in all intravenous orders. Patients may experience adverse consequences or risks associated with inappropriate infusion. Meanwhile, there is growing pressure on the chemotherapy unit to deliver treatment quickly, efficiently, and safely, and thus it is very necessary to improve the chemotherapy process and service to cancer patients. Clinicians should consider how to further standardize infusion therapy, and innovate new infusion strategies to increase efficacy, reduce toxicity, improve patient satisfaction and save health resource costs. Sporadic studies have evaluated the effects of infusion rates of anticancer agents on clinical outcomes, economic benefits, and administration efficiency. However, an update review has not been available.
UNASSIGNED: Relevant literature was identified by search of PubMed until September 2023.
UNASSIGNED: Infusion rates may have significant effect on the efficacy of anticancer agents (e.g., methotrexate, fluorouracil, and arsenic trioxide). Slow infusion is safer for platinum compounds, doxorubicin and carmustine, whereas fast infusion is safer than slow infusion of gemcitabine. Optimal flow rates of paclitaxel and fluorouracil are based on the balance between multiple risks of toxicity. Optimal infusion rate may bring economic benefits. If efficacy and safety are not compromised, shortened infusion may result in higher patient satisfaction, improved institutional efficiency and more nursing time available for other activities (e.g., biosimilar products, endostar). Other concerns about infusion rate include clinical indications (eg, paclitaxel and rituximab, methotrexate), severity and type of hypersensitivity reactions (e.g., platinum compounds), formulation features (e.g., paclitaxel, doxorubicin), and genetic polymorphism (e.g., gemcitabine, methotrexate).
UNASSIGNED: The latest knowledge of infusion rate concerns will enhance the appropriateness and accuracy in intravenous administration. Interdisciplinary teams should collaborate and implement relevant risk management and healthcare policy. It is worthwhile to conduct comparative studies of intravenous therapy with different infusion speeds.